Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 1Phase 2 1

Status

Completed 6Unknown 5Not yet recruiting 5Recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6Breast 1

Conditions

Ovarian Neoplasms 6Neoplasms 3Triple Negative Breast Neoplasms 2Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Metastatic Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Advanced Solid Tumor 1Advanced Pancreatic Cancer 1Advanced Cancer 1

Interventions

Paclitaxel 177Carboplatin 177Bevacizumab 72Topotecan 55liposomal doxorubicin 54Gemcitabine 53Cisplatin 46Docetaxel 39Cyclophosphamide 37olaparib 32Filgrastim 31pembrolizumab 29Doxorubicin 26niraparib 24Taxes 23Drug Therapy 23Peripheral Blood Stem Cell Transplantation 20Etoposide 17veliparib 15Nivolumab 14sargramostim 13Surveys and Questionnaires 13Immunoglobulin G 13Disulfides 13pazopanib 12Ifosfamide 12Albumin-Bound Paclitaxel 12durvalumab 11atezolizumab 11Trabectedin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Ovarian Neoplasms × fluzoparib × Clear all
NCT03863860 2025-07-03

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Completed
252 enrolled
Gynecologic

Ovarian Neoplasms

NCT04517357 2025-02-24

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
100 enrolled
Gynecologic

Ovarian Neoplasms

NCT04718740 2023-08-14

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
33 enrolled
Gynecologic

Ovarian Neoplasms

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
98 enrolled
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03509636 2022-07-01

A Study of Fluzoparib(SHR-3162)in BRCA1/2-mutant Relapsed Ovarian Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
113 enrolled
Gynecologic

Ovarian Neoplasms

NCT02575651 2019-06-17

A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
79 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡